All In Biotech

NDA 018035 · Jubilant

Draximage Mdp-10

Technetium Tc-99m Medronate · Injection

Last checked: Nov 20, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Nov 28, 1978

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

2 Phase 3, 0 recruiting

FAERS reports

2

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 5, 2025.

INDICATIONS AND USAGE MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 28, 1978 Original approval · Type 5 - New Formulation or New Manufacturer Review
2 products under this application
  • DRAXIMAGE MDP-10 · TECHNETIUM TC-99M MEDRONATE N/A · INJECTABLE, INJECTION · Discontinued
  • DRAXIMAGE MDP-25 · TECHNETIUM TC-99M MEDRONATE N/A · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Medronate" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chills1
  • dysphagia1
  • eye oedema1
  • eye pain1
  • hypoaesthesia1
  • mucosal inflammation1
  • stomatitis1
  • visual impairment1
  • vomiting1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20141

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Jubilant · Also marketed as Draximage Mdp-25

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.